Although NK-1R antagonists may be therapeutic in inhibiting CCA tumor growth, current studies are limited and expression levels of TAC1 and NK-1R in human CCA tumor tissues and correlation with metastases or survival rates are still undefined. The gene discussed is TACR1; the disease is neoplasm.